Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cash aid for childhood cancer families tested in new study

NCT ID NCT06283251

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether families of children with cancer are willing to join a program that provides financial support. About 40 families will be randomly assigned to either receive the PediRISE support program or standard care. The goal is to see if the program is feasible and can help reduce financial stress and disparities.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Up to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Cohort 1: Poverty-exposed children with cancer receiving front-line cancer-directed therapy 1. Child diagnosed with de novo cancer 2. Child has established care at a study site and initiated cancer directed therapy in the prior 2-months 3. Child planned to receive at least 4-months of cancer-directed therapy at study site from time of diagnosis per initial cancer treatment plan 4. Child is \<18 years at time of enrollment 5. Parent/guardian screened positive for self-reported low-income (\<200% FPL) 6. Family primary residence in CA, CT, MA, ME, NH, NJ, NY or RI 7. Provider approval for permission to approach Cohort 2: Poverty-exposed children with cancer undergoing HSCT 1. Child undergoing allogeneic HSCT for treatment of cancer 2. Child has established care at a study site and is between 30 days prior to start of planned conditioning through day +7 of HSCT at time of enrollment 3. Child planned to receive follow-up care after discharge for HSCT at study site 4. Child is \<18 years at the time of enrollment 5. Parent/guardian screen positive for self-reported low-income (\<200% FPL) 6. Family primary residence in CA, CT, MA, ME, NH, NJ, NY or RI 7. Provider approval for permission to approach Exclusion Criteria Cohort 1: Poverty-exposed children with cancer receiving front-line cancer-directed therapy 1. Planned transfer of child to a non-DFCI or non-Columbia facility for cancer-directed therapy 2. Foreign national family receiving care as an Embassy-pay patient 3. Child is enrolled on embedded correlative health equity aims of open or upcoming clinical drug trials which are powered on descriptive parent-reported poverty data (e.g. AALL1731, DFCI 25-001). Co-enrollment on a poverty intervention study would confound the specified endpoints of these open trial correlative studies 4. Child or household member receiving SSI Cohort 2: Poverty-exposed children with cancer undergoing HSCT 1. Planned transfer of child to a non-DFCI, non-Columbia, or non UCSF facility for cancer-directed therapy 2. Foreign national family receiving care as an Embassy-pay patient 3. Child is enrolled on embedded correlative health equity aims of open or upcoming clinical drug trials which are powered on descriptive parent-reported poverty data (e.g. AALL1731, DFCI 25-001). Co-enrollment on a poverty intervention study would confound the specified endpoints of these open trial correlative studies 4. Child previously received RISE intervention 5. Child or household member receiving SSI

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Boston Children's Hospital

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Columbia University Medical Center

    RECRUITING

    New York, New York, 10032, United States

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • University of California San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.